Last reviewed · How we verify
Ferric carboxymaltose infusion
At a glance
| Generic name | Ferric carboxymaltose infusion |
|---|---|
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY (PHASE1)
- Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation (PHASE4)
- Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery (PHASE4)
- The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF) (PHASE4)
- Comparison of the Mean Change in Hemoglobin With Ferric Carboxymaltose and IV Iron Sucrose in Anemic Antenatal Patients (NA)
- Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial (NA)
- Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression (PHASE4)
- Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ferric carboxymaltose infusion CI brief — competitive landscape report
- Ferric carboxymaltose infusion updates RSS · CI watch RSS
- NYU Langone Health portfolio CI